Last reviewed · How we verify
NCT05804383
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
Completed
Phase 1
Last updated 6 November 2025
What this trial tests
Phase 1 trial testing BMS-984923 in Alzheimer's Disease in 51 participants. Completed in 15 October 2025.
Timeline
28 March 2023
Primary endpoint
15 July 2025
15 July 2025
15 October 2025
Quick facts
| Lead sponsor | Allyx Therapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | basic science |
| Enrollment | 51 |
| Start date | 28 March 2023 |
| Primary completion | 15 July 2025 |
| Estimated completion | 15 October 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- BMS-984923 — full drug profile →
- Placebo
Conditions studied
- Alzheimer's Disease — all drugs for Alzheimer's Disease →
Sponsor
Allyx Therapeutics — full company profile →
Who can join
Adults 50 to 80, any sex, with Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Alzheimer's disease drug development pipeline: 2024.
Cummings J, Zhou Y, Lee G, Zhong K, et al · · 2024 · cited 209× · PMID 38659717 · DOI 10.1002/trc2.12465 -
Recent Advances in Therapeutics for the Treatment of Alzheimer's Disease.
Thawabteh AM, Ghanem AW, AbuMadi S, Thaher D, et al · · 2024 · cited 26× · PMID 39519769 · DOI 10.3390/molecules29215131 -
Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer's Pathogenesis.
Almeida ZL, Vaz DC, Brito RMM. · · 2025 · cited 19× · PMID 39446217 · DOI 10.1007/s12035-024-04543-4 -
Aging-dependent loss of functional connectivity in a mouse model of Alzheimer's disease and reversal by mGluR5 modulator.
Mandino F, Shen X, Desrosiers-Grégoire G, O'Connor D, et al · · 2025 · cited 11× · PMID 39424929 · DOI 10.1038/s41380-024-02779-z -
Pharmacology, Signaling and Therapeutic Potential of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators.
Kos JA, Langiu M, Hellyer SD, Gregory KJ. · · 2024 · cited 3× · PMID 39698283 · DOI 10.1021/acsptsci.4c00213 -
Targeting Amyloid-β Proteins as Potential Alzheimer's Disease Therapeutics: Anti-Amyloid Drug Discovery, Emerging Therapeutics, Clinical Trials and Implications for Public Health.
Abduljawad AA, Alkinani KB, Zaakan A, AlGhamdi AS, et al · · 2025 · cited 1× · PMID 41304975 · DOI 10.3390/ph18111731 -
mGluR5 as a Potential Orchestrator of Astrocyte Interactions in Neurological Disorders.
Kim J, Lee J, Song H, Koo JW, et al · · 2025 · cited 1× · PMID 40964490 · DOI 10.1155/np/7259018 -
Small Molecule Therapeutics Targeting Amyloid-β in Alzheimer's Disease: Mechanisms, Clinical Progress, and Future Strategies.
Park I, Lee D, Hong RS, Kim HY, et al · · 2026 · PMID 41906332 · DOI 10.5607/en25040
Verify or expand the search:
- PubMed search for NCT05804383
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BMS-984923
Trials testing the same drug.
- NCT06632990 — A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substra · Phase 1 · active not recruiting
- NCT05817643 — Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers · Phase 1 · unknown
- NCT04805983 — Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923 · Phase 1 · completed
Other recruiting trials for Alzheimer's Disease
Currently open trials in the same condition.
- NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
- NCT07234942 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants Wit · Phase 1 · recruiting
- NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
- NCT07214727 — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease · Phase 1 · recruiting
- NCT07105709 — Open-label Extension Study in Participants With Early Alzheimer's Disease · Phase 2 · recruiting
Other Allyx Therapeutics trials
Trials by the same sponsor.
- NCT06632990 — A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substra · Phase 1 · active not recruiting
- NCT06309147 — A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's · Phase 1 · unknown
- NCT05817643 — Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05804383 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Allyx Therapeutics
- Last refreshed: 6 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05804383.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing